Evidence map›Paper›PMID 27758070›Full record

ArticleJournal of cellular and molecular medicine2017

HIV-1 promonocytic and lymphoid cell lines: an in vitro model of in vivo mitochondrial and apoptotic lesion.

Constanza Morén, Ingrid González-Casacuberta, Carmen Álvarez-Fernández, Maria Bañó, Marc Catalán-Garcia, Mariona Guitart-Mampel, Diana Luz Juárez-Flores, Ester Tobías, José Milisenda, Francesc Cardellach and 3 more

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Barriers for HIV Cure: The Latent Reservoir.AIDS research and human retroviruses · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Constanza MorénMuscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.
Ingrid González-CasacubertaMuscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.
Carmen Álvarez-FernándezCellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Infectious Diseases Unit-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.
Maria BañóMuscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.
Marc Catalán-GarciaMuscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.
Mariona Guitart-MampelMuscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.
Diana Luz Juárez-FloresMuscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.
Ester TobíasMuscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.
José MilisendaMuscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.
Francesc CardellachMuscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.
Josep Maria GatellCellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Infectious Diseases Unit-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.
Sonsoles Sánchez-PalominoCellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Infectious Diseases Unit-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.
Glòria GarrabouMuscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine-University of Barcelona, Internal Medicine Department-Hospital Clínic of Barcelona (HCB), Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To characterize mitochondrial/apoptotic parameters in chronically human immunodeficiency virus (HIV-1)-infected promonocytic and lymphoid cells which could be further used as therapeutic targets to test pro-mitochondrial or anti-apoptotic strategies as in vitro cell platforms to deal with HIV-infection. Mitochondrial/apoptotic parameters of U1 promonocytic and ACH2 lymphoid cell lines were compared to those of their uninfected U937 and CEM counterparts. Mitochondrial DNA (mtDNA) was quantified by rt-PCR while mitochondrial complex IV (CIV) function was measured by spectrophotometry. Mitochondrial-nuclear encoded subunits II-IV of cytochrome-c-oxidase (COXII-COXIV), respectively, as well as mitochondrial apoptotic events [voltage-dependent-anion-channel-1(VDAC-1)-content and caspase-9 levels] were quantified by western blot, with mitochondrial mass being assessed by spectrophotometry (citrate synthase) and flow cytometry (mitotracker green assay). Mitochondrial membrane potential (JC1-assay) and advanced apoptotic/necrotic events (AnexinV/propidium iodide) were measured by flow cytometry. Significant mtDNA depletion spanning 57.67% (P < 0.01) was found in the U1 promonocytic cells further reflected by a significant 77.43% decrease of mitochondrial CIV activity (P < 0.01). These changes were not significant for the ACH2 lymphoid cell line. COXII and COXIV subunits as well as VDAC-1 and caspase-9 content were sharply decreased in both chronic HIV-1-infected promonocytic and lymphoid cell lines (<0.005 in most cases). In addition, U1 and ACH2 cells showed a trend (moderate in case of ACH2), albeit not significant, to lower levels of depolarized mitochondrial membranes. The present in vitro lymphoid and especially promonocytic HIV model show marked mitochondrial lesion but apoptotic resistance phenotype that has been only partially demonstrated in patients. This model may provide a platform for the characterization of HIV-chronicity, to test novel therapeutic options or to study HIV reservoirs.

Indexed as

ApoptosisModels, BiologicalCell LineDNA, MitochondrialElectron Transport Complex IVHIV-1HumansLymphocytesMitochondriaMonocytesProtein SubunitsVoltage-Dependent Anion Channel 1DNA, MitochondrialElectron Transport Complex IVProtein SubunitsVoltage-Dependent Anion Channel 1apoptosiscell modelsHIV-infectionHIV progressionin vitro modellingmitochondria

Identifiers

PMID27758070
PMCPMC5264141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.